<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321617</url>
  </required_header>
  <id_info>
    <org_study_id>7459</org_study_id>
    <secondary_id>R61MH112800-01</secondary_id>
    <nct_id>NCT03321617</nct_id>
  </id_info>
  <brief_title>Glutamate Reducing Interventions in Schizophrenia</brief_title>
  <official_title>Glutamate Reducing Interventions in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants will be administered several doses of POMA (low and high doses) over 14 days to
      individuals at clinical high risk for developing psychosis and use MRI brain imaging to
      determine whether these doses of POMA are affecting glutamate levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomized, phase 1b, multiple dose trial of 14 days of treatment with POMA
      (80 mg, 160 mg, 240 mg, 320 mg) in clinical high risk patients to determine which dose, if
      any, reduces glutamate and metabolism using MRI techniques. The GO NO-GO decision will be
      whether or not any dose tested in the R61 phase of the trial decreases left CA1 cerebral
      blood volume (CBV).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized, phase 1b, multiple dose trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Identity of medications will be blinded having every subject take an equal number of pills (using identical looking tables of placebo)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left CA1 CBV from baseline to 14 days</measure>
    <time_frame>Baseline to 14 days</time_frame>
    <description>Effect of POMA on left CA1 CBV</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Clinical High Risk for Psychosis</condition>
  <arm_group>
    <arm_group_label>POMA 40mg BID (80mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will take 40mg pomaglumetad methionil (POMA) twice a day for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>POMA 80mg BID (160 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will take 80 mg pomaglumetad methionil (POMA) twice a day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>POMA 120mg BID (240mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will take 120 mg pomaglumetad methionil (POMA) twice a day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>POMA 160 mg BID (320 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will take 160 mg pomaglumetad methionil (POMA) twice a day for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomaglumetad methionil</intervention_name>
    <description>metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist</description>
    <arm_group_label>POMA 40mg BID (80mg)</arm_group_label>
    <arm_group_label>POMA 80mg BID (160 mg)</arm_group_label>
    <arm_group_label>POMA 120mg BID (240mg)</arm_group_label>
    <arm_group_label>POMA 160 mg BID (320 mg)</arm_group_label>
    <other_name>POMA; LY2140023</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capacity to provide informed consent

          -  Currently using a reliable form of birth control

        Exclusion Criteria:

          -  Metal implants in body or a history of metal working

          -  Lifetime diagnosis of asthmatic symptoms within the past 3 years or known sensitivity
             to contrast agents

          -  Lifetime diagnosis of renal failure/disease

          -  Acute neurological, neuroendocrine, or medical disorder including renal insufficiency
             (CrCl&lt;40 mL/min/1.73m2)

          -  Lifetime diagnosis of hypertension or diabetes or seizure disorder

          -  IQ&lt;70

          -  Acute risk for suicide and/or violence

          -  Pregnant lactating

          -  Current abuse of substances (alcohol, cocaine, stimulants, cannabis, opiates, sedative
             hypnotics)

          -  Current use or anticipated need for antipsychotics or mood stabilizers (all
             antipsychotics, also depakote, lithium, lamotrogine, pregabalin or any med with a
             mechanism of action like gabapentin), probenecid, selective serotonin reuptake
             inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors

          -  More than one previous gadolinium scan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Small, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ragy Girgis, MD</last_name>
    <phone>646-774-5553</phone>
    <email>ragy.girgis@nyspi.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marlene Carlson, MPH</last_name>
    <phone>646-774-8436</phone>
    <email>marlene.carlson@nyspi.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

